In this cohort study of 269 064 propensity score–matched adult patients with type 2 diabetes, SGLT2i initiation was associated with a higher prevalence of erythrocytosis compared with dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.